Kevin Oliver

Member of executive Committee reporting to CEO. Spearheading readiness for global expansion—InnoCare 2.0—and establishing the organization as a global innovator and respected small molecule and biologics (monoclonal antibodies, bispecifics, ADCs) platform company. Lead worldwide business development and alliance management with accountability for developing, strengthening, and commercializing value-added alliances, joint ventures and other outbound strategic transactions targeting patients globally.

Member of Executive Committee, reporting to the CEO and board member. Strategic and operational oversight of Business Development, External Innovation, and Alliance Management. Responsible for enhancing company’s reputation as partner of choice in neurological and rare disease drug research, development and commercialization. Executed and managed multiple transactions in neurological and rare/orphan disease leading directly to pipeline value and sales growth to $1B+ revenue.

Reported to Founder Chairman. Led global expansion and operations outside China as COO, including strategy, build, and operation of the 70 person Boston Innovation Center laboratory and London, UK offices. Key in hiring US-based executive leadership team (CMO, CSO, Regulatory Affairs, General Counsel, HR) and oversaw lab operations across autoimmune disease, neuroscience, oncology, cell and gene therapy, RNA therapeutics, and multi-specific antibody platforms.

Reported to the Founder Chairman and served on the Executive Committee, championing the company’s globalization strategy. Responsible for positioning company as partner of choice among leading Chinese biopharmaceuticals across the US, UK, EU, China, Japan, and Korea and transacted in these regions. Provided strategic leadership to regional and functional BD and Alliance heads and 7+ VP/Executive Directors, overseeing a 26-person organization accountable for significant partnership growth and performance.

Served in strategic advisory capacity to newco/spinout. Simnova is leading the development of innovative cell therapeutics for the treatment of cancer using CAR-T and CAR-NK and other modalities,

Reported to Alcon's SVP, Head of Corporate Strategy and Business Development, and Novartis' Global Head of Business Development. Led a prolific team strengthening Alcon’s near-term and future pipeline by in licensing and M&A, as well as ensuring productive strategic partnerships by creating first-rate alliance and integration management, earning back-to-back recognition from the Association of Strategic Alliance Professionals.

Spearheaded strategic out-licensing / divestment oversight for a portfolio of 60+ late-discovery to commercial-stage programs, spanning biologics and small molecule pharmaceuticals across dermatology, CNS, ophthalmology, inflammation/autoimmune disease, and oncology. Served as core deal-team lead for major product and franchise divestitures, securing over $900M in upfront payments, including the $600M divestiture of the Ophthalmology Business Unit to Santen (ex-US rights) and a $52M transaction with Akorn Pharmaceuticals (US rights).

In partnership with respective Franchise Executive Leadership, I led the global licensing strategy, search, evaluation and due diligence for early and late stage for key franchises including Neuroscience and Ophthalmology and Drug Delivery and Formulation (all TAs). As a key contributor to an exemplary business development and external innovation team, established Merck as Boston Consulting Group’s respected biopharma preferred partner accolades year-on-year 2011-2014

Career expansion into Business Development and External Scientific Affairs. Responsible for all negotiated research and (co)development agreements originating in UK and most EU Merck facilities. Established cross-functional and cross-border relationships and operational efficiencies, including working with outside legal counsel to create research and consortium agreements compliant with laws in multiple geographies.

Led pioneering bench research and innovation spanning small molecules, peptides, biologics, and RNAi therapeutics. Served as lead antibody engineer and epitope designer for technical and therapeutic applications. Authored 26 primary publications and book chapters and delivered more than 50 conference presentations, advancing the scientific profile of the organization. Validated CGRP antagonists as a novel migraine target, helping establish an entirely new treatment category.